Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
Timothy P DiPeriKurt W EvansBailiang WangMing ZhaoArgun AkcakanatMaria Gabriela RasoYasmeen Q RizviXiaofeng ZhengAnil KorkutKaushik VaradarajanBurak UzunparmakEcaterina E Ileana DumbravaShubham PantJaffer A AjaniPaula R PohlmannVanessa B JensenMilind M JavleJordi Rodon AhnertFunda Meric-BernstamPublished in: Cancer discovery (2024)
We demonstrate that PDXs can be developed from pretreatment and postprogression biopsies in clinical trials and may represent a powerful preclinical tool. We identified amplification of MET as a potential mechanism of acquired resistance to the HER2 inhibitor zanidatamab and MET inhibitors alone and in combination as a therapeutic strategy. This article is featured in Selected Articles from This Issue, p. 695.